Treatment progress of relapsed/refractory diffuse large B-cell lymphoma
10.3760/cma.j.issn.1009-9921.2018.12.004
- VernacularTitle:复发难治弥漫大B细胞淋巴瘤治疗进展
- Author:
Jiaqi QIN
1
;
Wei XU
Author Information
1. 210029,南京医科大学第一附属医院 江苏省人民医院血液科
- Keywords:
Lymphoma,large B-cell,diffuse;
Recurrence;
Refractory;
Treatment;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2018;27(12):716-720,724
- CountryChina
- Language:Chinese
-
Abstract:
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy and who are not candidates for stem cell transplantation have limited effective treatment options, resulting in a poor prognosis, thus, treatments with novel mechanisms of action are urgently needed. In the 60th American Society of Hematology (ASH) Annual Meeting, detailed reports focused on the research progresses of single agent, drug combination and chimeric antigen receptor T cell (CAR-T) therapy, providing more treatment options for R/R DLBCL patients.
